Incyte Corporation vs Seagate Technology Holdings PLC — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Seagate Technology Holdings PLC trades at $905 (market cap $181.56B). The key difference: Seagate Technology Holdings PLC is far larger — about 7.9× Incyte Corporation's market cap, and Seagate Technology Holdings PLC pays a 0.37% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | STX | |
|---|---|---|
Market Cap | $23.11B | $181.56B |
Sector | Health | Technology |
52-Week High | $118.52 | $1.09K |
52-Week Low | $67.38 | $146.59 |
Enterprise Value | $19.13B | $184.59B |
Dividend Yield | — | 0.37% |
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Seagate Technology (STX) trades at $891.23, up 13.25% over the past 24 hours, with strong recent earnings beats and bullish analyst sentiment. The stock shows bearish technical signals but benefits from robust profitability metrics including a 21.6% net income margin and 96.27% ROE. Recent news highlights AI-driven storage demand as a key growth catalyst, with the company set to report Q2 2026 earnings on July 28, 2026.
Outlook remains positive due to AI infrastructure expansion and consistent earnings outperformance, though high valuation ratios and negative shareholder equity pose risks. Analyst consensus price target of $987.86 suggests upside potential, but investors should monitor debt levels and competitive pressures in the storage sector.
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →